Neurocrine Biosciences, Inc. (NBIX) Stock Analysis
Range Bound setup · Temp Headwind edge
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $148.02. Weak momentum — blocks BUY_NOW at $158.35. Engine's entry $148.02 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: INGREZZA; Thin upside margin: 9.6%.
Neurocrine Biosciences is a commercial-stage neuroscience biopharma with FDA-approved treatments for tardive dyskinesia and Huntington's chorea (INGREZZA) and classic CAH (CRENESSITY), plus a diversified mid-to-late stage pipeline. INGREZZA generated $2.51B in 2025 net product... Read more
Wait for pullback to $148.02. Weak momentum — blocks BUY_NOW at $158.35. Engine's entry $148.02 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: INGREZZA; Thin upside margin: 9.6%. Chart setup: RSI 53 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.45, quality 8.7/10, growth 10.0/10). Score 6.8/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Neurocrine Biosciences, Inc.
Latest news
- NEWS AMG National Trust Bank Acquires Shares of 12,326 Neurocrine Biosciences, Inc. $NBIX - MarketBeat — MarketBeat neutral
- NEWS Neurocrine Biosciences Hits New Highs On Earnings Surge - Investor's Business Daily — Investor's Business Daily positive
- NEWS Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock? - Zacks Investment Research — Zacks Investment Research positive
- NEWS Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock? - Yahoo Finance — Yahoo Finance positive
- NEWS Robeco Institutional Asset Management B.V. Purchases 85,076 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat — MarketBeat positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductINGREZZA10-K Item 1: 'INGREZZA net product sales were $2.51 billion for 2025 ... and accounted for a significant portion of our total net product sales during each of these years.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $148.02. Weak momentum — blocks BUY_NOW at $158.35. Engine's entry $148.02 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: INGREZZA; Thin upside margin: 9.6%. Chart setup: RSI 53 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.45, quality 8.7/10, growth 10.0/10). Target $173.60 (+9.6%), stop $137.85 (−14.9%), Setup A.R:R 2.6:1. Score 6.8/10, moderate confidence.
Take-profit target: $173.60 (+11.9% upside). Target $173.60 (+9.6%), stop $137.85 (−14.9%), Setup A.R:R 2.6:1. Stop-loss: $137.85.
Concentration risk — Product: INGREZZA; Thin upside margin: 9.6%; Negative momentum.
Neurocrine Biosciences, Inc. trades at a P/E of 24.6 (forward 12.6). TrendMatrix value score: 6.7/10. Verdict: Buy (Wait for Entry).
36 analysts cover NBIX with a consensus score of 4.3/5. Average price target: $193.
What does Neurocrine Biosciences, Inc. do?Neurocrine Biosciences is a commercial-stage neuroscience biopharma with FDA-approved treatments for tardive dyskinesia...
Neurocrine Biosciences is a commercial-stage neuroscience biopharma with FDA-approved treatments for tardive dyskinesia and Huntington's chorea (INGREZZA) and classic CAH (CRENESSITY), plus a diversified mid-to-late stage pipeline. INGREZZA generated $2.51B in 2025 net product sales, representing a significant portion of total revenues; CRENESSITY contributed $301.2M in its first full launch year.